

OPEN ACCESS
Full open access to this and thousands of other papers at <http://www.la-press.com>.

Repopulation of Ovarian Cancer Cells After Chemotherapy

Carlos M. Telleria

Division of Basic Biomedical Sciences, Sanford School of Medicine of The University of South Dakota, 414 East Clark Street, Vermillion, SD. Corresponding author email: carlos.telleria@usd.edu

Abstract: The high mortality rate caused by ovarian cancer has not changed for the past thirty years. Although most patients diagnosed with this disease respond to cytoreductive surgery and platinum-based chemotherapy and undergo remission, foci of cells almost always escape therapy, manage to survive, and acquire the capacity to repopulate the tumor. Repopulation of ovarian cancer cells that escape front-line chemotherapy, however, is a poorly understood phenomenon. Here I analyze cancer-initiating cells, transitory senescence, reverse ploidy, and cellular dormancy as putative players in ovarian cancer cell repopulation. As part of the standard of care, ovarian cancer patients do not receive treatment between primary cytotoxic therapy and clinical relapse. Understanding the mechanisms driving cellular escape from chemotherapy should lead to the development of low toxicity, chronic treatment approaches that can be initiated right after primary therapy to interrupt cell repopulation and disease relapse by keeping it dormant and, therefore, subclinical.

Keywords: ovarian cancer, repopulation, chemotherapy

Cancer Growth and Metastasis 2013:6 15–21

doi: [10.4137/CGM.S11333](https://doi.org/10.4137/CGM.S11333)

This article is available from <http://www.la-press.com>.

© the author(s), publisher and licensee Libertas Academica Ltd.

This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.



Chemotherapy in Ovarian Cancer has Limited Efficacy

Despite vast research efforts made over the past fifty years, the war against cancer remains to be won. The improvement in overall patient survival is mainly a consequence of early diagnosis, rather than due to better treatment approaches. We have made great progress in understanding the mechanisms driving carcinogenesis and cancer progression at the molecular level, which brought about the concept of targeted therapy designed to disengage a particular pathway, a unique and essential process for the survival of the cancer cells. Targeted therapy seemed ideal for eradicating cancer; however, its success in the clinic has been limited.¹

Hence, in the treatment front, the war against cancer is still fought mainly with highly cytotoxic chemotherapeutic drugs that do not spare rapidly dividing non-cancer cells. Due to their toxicity, the amount of drug to be administered to patients is limited to the so-called patient-specific maximal tolerated dose. The drugs also have to be spaced to allow bone marrow recovery. Overall, removal of the tumor cells is not guaranteed, with many cancers recurring sooner or later, and the patients becoming cancer survivors rather than cancer cured.

Prospects are particularly disheartening in ovarian cancer. The disease is rare; yet, it represents the most deadly gynecologic malignancy with a five-year survival rate that has only improved nine percent in the past thirty years and a dismal overall survival rate that has remained stagnant for over fifty years (reviewed in).²⁻⁷ Due to a lack of efficient early diagnostic tools, most patients are diagnosed when already symptomatic, with the disease progressing within the peritoneal cavity and beyond.⁸ Patients undergo cytoreductive surgery, but due to the nature of the growths in the peritoneal cavity, it cannot guarantee total elimination of the disease since microscopic and sometimes even macroscopic residual tumors cannot be totally resected (reviewed in).⁹ Surgery is followed by cycles of chemotherapy based on the combination of platinum and taxane agents.^{9,10} Most patients respond favorably at first to this treatment, but the disease usually recurs within twelve to eighteen months with a platinum-resistant phenotype, leaving doctors with limited tools to maneuver within the available alternative chemotherapeutic armamentarium (reviewed in).²⁻⁴

Ovarian Cancer Cells Escape Chemotherapy

Platinum-derivatives are DNA cross-linking agents,¹¹⁻¹⁴ whereas taxanes are microtubule stabilizers.¹⁵ These drugs kill rapidly dividing ovarian cancer cells, and operate in a synergistic manner;¹⁶ however, they also cause damage to normal tissues, thus limiting their safe dosage. The main restraining factors for therapeutic dosage are renal toxicity, neurotoxicity, myelosuppression, and peripheral neuropathy (reviewed in).^{17,18} To balance tumor-specific toxicity and unwanted side effects, the most common treatment regimen consists of six cycles, spaced every three weeks, of a taxane (eg, paclitaxel) followed by a DNA platinating agent (eg, cisplatin or carboplatin), which are given at the patient's specific maximal tolerated doses.^{9,10} As a consequence of the required waiting periods between chemotherapeutic rounds, a largely overlooked phenomenon takes place: the repopulation of cancer cells between treatment intervals (reviewed in).^{19,20}

The escape of cancer cells from chemotherapy was first attributed to the complexity of the circulation within the solid tumors, with an anarchic distribution of the newly formed blood vessels. As a consequence of this complexity, drugs may not reach all cells within the tumor with an efficient toxic concentration.²¹ The rationale given for *in vivo* repopulation, however, cannot explain why maximal tolerated doses and times of exposure of chemotherapeutic drugs tailored to treat monolayers of ovarian cancer cells *in vitro* do not kill the entire population of cells, leaving behind live cells with the capacity to recreate the culture.^{22,23} The few cells that escape platinum-based therapy have the capacity to repopulate the culture at an accelerated pace,²³ a concept known as accelerated repopulation.¹⁹ Repopulation of cancer cells in culture cannot be attributed to the acquisition of resistance to platinum, because the cells need to be exposed to dose escalation for several months before developing the capacity to become refractory to clinically relevant doses of platinum.²⁴

Although the concept of cancer repopulation was coined from *in vivo* experience and involves solid tumor regrowth in between chemotherapy or radiotherapy intervals,^{19,25} it can be recreated in a culture if cells in dishes are exposed to concentrations and exposure times reminiscent to those used in the clinic. Ovarian cancer patients are treated intravenously with



a sequence of a taxane for three hours followed by a platinum-derivative for one hour. Under this regimen, the concentrations in circulation for the most standard taxane used, paclitaxel, do not reach beyond 50 to 100 nanomolar, whereas those for the canonical platinating agent cisplatin range between 7 to 10 micromolar.^{26–29} Since the implementation in the clinic of platinum-taxane therapy, a large body of research uncovered the molecular mechanisms triggered by these drugs in terms of cell death and drug resistance (reviewed in).^{15,30} Many such studies, however, did not take into consideration the dosage and/or the time of exposure, limiting the preclinical relevance of the results obtained.

To illustrate the feasibility of recreating repopulation of ovarian cancer cells following platinum chemotherapy, we utilized the cisplatin hyper-sensitive cell line OV2008, which is defective in the Fanconi anemia pathway required for repairing cisplatin-induced DNA cross-links.^{31,32} We exposed the cells to two times the clinically achievable concentration of cisplatin, but limited the time of exposure to one hour. Under these conditions, over eighty percent of the cells in culture die within four days of platinum removal. The few cells that remained in the dish were mostly giant, multinucleated and vacuolated, and managed to perpetuate the culture over time.²³ A similar phenomenon of repopulation took place when we exposed A2780, IGROV-1 and SK-OV-3 ovarian cancer cells to the combination cisplatin and paclitaxel at concentrations twice of what is clinically relevant (ie, supra-pharmacological doses). We used this approach to maximize the cytotoxicity of the drugs, but tailored the time of exposure to those clinically relevant.²² The combination cisplatin-paclitaxel was very efficient in killing the majority of the cells representing ovarian cancers of different genetic backgrounds; yet, there were cells escaping the therapy that with time repopulated the culture—albeit the drugs were utilized at higher doses than one could possibly achieve in vivo. These data suggest that escape from chemotherapy of otherwise chemosensitive ovarian cancer cells is an intrinsic phenomenon, not related to long-term acquisition of resistance.

Potential Molecular Mechanism(s) Driving Ovarian Cancer Cellular Escape from Chemotherapy

There are several mechanisms that potentially clarify why and how a so-called chemosensitive population of

ovarian cancer cells escapes therapy and repopulates over time, thus most likely elucidating tumor relapse. However, mostly due to the scarcity of experimental model systems available, at present there is only partial, fragmented evidence to explain tumor cell repopulation after chemotherapy. The mechanisms proposed below may not be mutually exclusive and could share some components. Further evidence should be generated to support each mechanism proposed under the specific conditions of ovarian cancer patients recurring after being initially responsive to taxane-platinum therapy.

Cancer-initiating cells

One appealing explanation is that epithelial ovarian cancer cells are heterogeneous, having a hierarchy within a progeny. Within such a hierarchy, more differentiated cells might be efficiently killed by the chemotherapy, whereas less differentiated cells with cancer-initiating properties (aka cancer progenitor cells or cancer stem cells)³³ survive and give rise to new transit-amplifying cells with the capacity to regenerate the culture. By definition, cancer-initiating cells have a distinct molecular signature, the capacity to self-renew although at a very low rate, and the capacity to give rise to a more differentiated progeny. The low division rate makes these cells intrinsically resistant to chemotherapy (reviewed in).^{34,35} In support of this theory, ovarian cancer cells with stemness properties have been successfully isolated from various ovarian cancer cell lines. A study showed ovarian cancer cells with stem-like properties expressing high levels of cell surface antigen CD44 (CD44+) and low levels of CD24 (CD24–).³⁶ Another group reported that CD44+ and aldehyde dehydrogenase positive (ALDH+) cells had enriched self-renewal and tumorigenic capacity,³⁷ whereas two other reports agree that ALDH defines a population of ovarian cancer stem cells that acquire more tumorigenic capacity if concurrently expressing CD133 (ie, ALDH+/CD133+).^{38,39} According to the cancer-stem cell theory, these ovarian cancer progenitor cells also depict reduced sensitivity to platinum-taxane therapy.^{33,36–44} The cancer-initiating cell enrichment might be even higher after chemotherapy in the hypoxic conditions normally found within solid tumors.⁴⁵

Transitory senescence

A rare percentage of cancer cells can escape chemotherapy by undergoing a transient arrest passing



through a senescence-like phenotype before regaining proliferation capacity. By definition, senescence has been considered an irreversible phase in which the cell cycle is permanently arrested as a consequence of telomere shortening (replicative senescence). The senescent cell has a particular phenotype characterized by a flat morphology. It also expresses senescence-associated beta galactosidase as a consequence of the enhancement of the perinuclear lysosome compartment, as well as chromatin remodeling, causing formation of heterochromatic foci, and a characteristic secretory phenotype (reviewed in).^{46–48} Senescence, however, can be induced by drugs (drug-induced senescence), and its irreversibility has been challenged. For instance, senescent cells with a low expression of p16^{Ink4} resume growth if p53 is inactivated,⁴⁹ p53 negative lung cancer cells can escape drug-induced senescence,⁵⁰ and colon cancer cells undergoing senescence after exposure to doxorubicin regain proliferation capacity.⁵¹ Furthermore, a study showed reversibility of senescence in melanoma cells upon overexpression of the inhibitor of apoptosis molecule, survivin.⁵² Finally, breast cancer cell cultures exposed to conventional chemotherapy display an emerging population of surviving cells with stem cell-like properties that have escaped the drug's toxicities by transitioning towards a short-term reversible, senescent-like non-cycling stage.⁵³ The escape cells expressed the stem cell markers CD133 and Oct-4, exhibited a low abundance of radical oxygen species (ROS), and had elevated antioxidant enzymes.⁵³ In agreement, non-small cell lung cancer cells exposed to lethal doses of epidermal growth factor receptor/tyrosine kinase inhibitor displayed escape cells enriched with the cancer initiating marker C133.⁵⁴

Drug-induced senescence is highly associated with formation of polyploid cells, some of which may escape senescence forming an aneuploidy progeny with the capacity to proliferate, thus limiting the efficacy of chemotherapy.⁵⁵ Accordingly, after cisplatin or cisplatin/paclitaxel treatments, we observed the accumulation of giant flat multinucleated polyploid cells that tend to disappear with time in culture, parallel to an increase in the number of smaller cells with high proliferation capacity and morphology similar to that of untreated cells.^{22,23} Whether the polyploid ovarian cancer cells that escape cisplatin-paclitaxel

therapy in our studies undergo transient senescence and/or express antigens characteristic of cancer initiating cells remains to be studied.

Reverse ploidy

When a culture of ovarian cancer cells is exposed to cytotoxic therapy, the majority of cells die; yet, the few surviving cells appear mostly degenerated, giant, and multinucleated.²³ Formation of giant multi-nucleated cells can be the consequence of a genotoxic insult followed by mitotic catastrophe, in which cells undergo cycles of DNA synthesis without cell division (endoreplication).⁵⁶ After a few endomitotic cycles, these cells mostly die as a consequence of mitotic disarray (mitotic death)⁵⁷ using a pathway of apoptosis or necrosis.⁵⁸ However, a scarce number of giant cells survive and adapt to the genotoxic environmental pressure. This survival occurs via a process termed depolyploidization⁵⁹ or reversible polyploidy,⁶⁰ which was proposed earlier as a different modality of cell division or 'neosis'.^{61,62} Mechanistically, the giant cells give rise to a progeny with a near diploid number of chromosomes (paradiploid) that is compatible with survival and division. This process of reverse ploidy associates with the activation of genes normally expressed during reduction division (meiosis).^{63,64} Furthermore, evidence shows that, following chemotherapy, the remainder of the giant cellular content, including extra-DNA and cytoplasmic material, seems to be cleared by autophagy.⁶⁵

Arising from cellular dormancy

Following chemotherapy there is a possibility of the persistence of cells in a dormant quiescent state with the capacity to regrow when environmental cues are appropriated (and references therein).^{66,67} One mechanism for single-cell dormancy in ovarian cancer was unveiled by the controlled expression of the tumor suppression gene aplasia Ras homolog member I (ARHI), leading to cell survival upon activation of autophagy in the presence of favorable growth factors within the tumor microenvironment.⁶⁸ These cells that survive the stress via autophagy-mediated dormancy may then emerge from such status and reenter the cell cycle, causing tumor relapse. Though the genetic and/or epigenetic factors that control how and when escape from dormancy takes place remain



to be determined, these appear to be related to the dialogue between the microenvironment, the cellular adhesion pathways, and the intracellular cell cycle machinery.⁶⁹

Abrogation of Ovarian Cancer Cellular Escape from Chemotherapy

Upon cytoreductive surgery and chemotherapy, ovarian cancer patients do not receive any other treatment while in remission until the disease actually recurs.^{70–72} Thus, patients have been without any treatment for very prolonged periods of time—twelve to eighteen months in the standard responder—where cells that escaped initial chemotherapy had the time to adapt to and hijack the microenvironment to repopulate and advance the disease again to a symptomatic state with the added hurdle of likely having acquired a chemotherapy resistant phenotype. It is imperative to take advantage of the time the patient is in remission to attack escape cancer cells by disengaging their repopulation capacity. Evidence suggests the feasibility of this consolidation therapeutic approach using cytostatic agents. For instance, we successfully prevented repopulation of escape ovarian cancer cells after platinum or platinum-taxane chemotherapy using steroids with antiprogestin and antiglucocorticoid activities.^{22,23} Likewise, others have used antiestrogens⁷³ or inhibitors of the mammalian target of rapamycin (mTOR)⁷⁴ to abrogate, respectively, escape of breast and prostate cancer cells from standard chemotherapy.

Despite the fact that improvement in chemotherapy to tackle ovarian cancer has been slim in the past decades, a better understanding of how cells escape clinical relevant doses of chemotherapy, together with the understanding of the mechanisms whereby cytostatic agents such as antiprogestins and antiglucocorticoids block cancer cell escape, should provide tools to discover new drugs capable of more effectively targeting the repopulation mechanism. Blocking tumor repopulation may be a promising way to conquer ovarian cancer not by eliminating the disease in its entirety, but by keeping it chronically dormant and subclinical.

Acknowledgements

I thank Dr. Alicia Goyeneche for her insightful and helpful comments, and Nahuel Telleria for copy-editing the manuscript.

Author Contributions

Wrote the first draft of the manuscript: CMT. Agree with manuscript results and conclusions: CMT. Made critical revisions and approved final version: CMT.

Funding

This work was supported by National Institutes of Health (NIH), National Cancer Institute (NCI) Grant R15CA164622 (to CMT).

Competing Interests

Author(s) disclose no potential conflicts of interest.

Disclosures and Ethics

As a requirement of publication author(s) have provided to the publisher signed confirmation of compliance with legal and ethical obligations including but not limited to the following: authorship and contributorship, conflicts of interest, privacy and confidentiality and (where applicable) protection of human and animal research subjects. The authors have read and confirmed their agreement with the ICMJE authorship and conflict of interest criteria. The authors have also confirmed that this article is unique and not under consideration or published in any other publication, and that they have permission from rights holders to reproduce any copyrighted material. Any disclosures are made in this section. The external blind peer reviewers report no conflicts of interest. Provenance: the authors were invited to submit this paper.

References

1. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. *Nat Rev Cancer*. 2012;12(7):487–93.
2. Romero I, Bast RC Jr. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. *Endocrinology*. 2012;153(4):1593–602.
3. Vaughan S, Coward JI, Bast RC Jr, et al. Rethinking ovarian cancer: recommendations for improving outcomes. *Nat Rev Cancer*. 2011;11(10):719–25.
4. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. *Nat Rev Cancer*. 2009;9(6):415–28.
5. Kuman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. *Hum Pathol*. 2011;42(7):918–31.
6. Bast RC Jr. Molecular approaches to personalizing management of ovarian cancer. *Ann Oncol*. 2011;22(Suppl 8):viii5–15.
7. Bast RC Jr, Mills GB. Dissecting “PI3 Kness”: The complexity of personalized therapy for ovarian cancer. *Cancer Discov*. 2012;2(1):16–8.
8. Lengyel E. Ovarian cancer development and metastasis. *Am J Pathol*. 2010;177(3):1053–64.
9. Tentes AA, Courcoutsakis N, Prasopoulos P. Combined cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced ovarian cancer. In: Farghaly SA, editor. *Ovarian Cancer—Clinical and Therapeutic Perspectives*. New York, NY: InTech; 2012:143–66.



10. Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. *Semin Oncol*. 2006;33(2 Suppl 6):S3–11.
11. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. *Cancer Treat Rev*. 2007;33(1):9–23.
12. Kelland L. The resurgence of platinum-based cancer chemotherapy. *Nat Rev Cancer*. 2007;7(8):573–84.
13. Jung Y, Lippard SJ. Direct cellular responses to platinum-induced DNA damage. *Chem Rev*. 2007;107(5):1387–407.
14. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Perez JM. Biochemical mechanisms of cisplatin cytotoxicity. *Anticancer Agents Med Chem*. 2007;7(1):3–18.
15. Horwitz SB. Mechanism of action of taxol. *Trends Pharmacol Sci*. 1992;13(4):134–6.
16. Jekunen AP, Christen RD, Shalinsky DR, Howell SB. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. *Br J Cancer*. 1994;69(2):299–306.
17. Ross AA, Miller GW, Moss TJ, et al. Immunocytochemical detection of tumor cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer. *Bone Marrow Transplant*. 1995;15(6):929–33.
18. Walker FE. Paclitaxel (TAXOL): side effects and patient education issues. *Semin Oncol Nurs*. 1993;9(4 Suppl 2):6–10.
19. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. *Nat Rev Cancer*. 2005;5(7):516–25.
20. Davis AJ, Tannock JF. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. *Lancet Oncol*. 2000;1:86–93.
21. Davis AJ, Tannock IF. Tumor physiology and resistance to chemotherapy: repopulation and drug penetration. *Cancer Treat Res*. 2002;112:1–26.
22. Gamarra-Luques CD, Goyeneche AA, Hapon MB, Telleria CM. Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. *BMC Cancer*. 2012;12:200.
23. Freeburg EM, Goyeneche AA, Telleria CM. Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment. *Int J Oncol*. 2009;34(3):743–55.
24. Coley HM. Development of drug-resistant models. *Methods Mol Med*. 2004;88:267–73.
25. Davis AJ, Chapman W, Hedley DW, Oza AM, Tannock IF. Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: pilot study. *Cytometry A*. 2003;51(1):1–6.
26. Ohtsu T, Sasaki Y, Tamura T, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. *Clin Cancer Res*. 1995;1(6):599–606.
27. Rowinsky EK, Jirutek M, Bonomi P, Johnson D, Baker SD. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. *Clin Cancer Res*. 1999;5(4):767–74.
28. Kurata T, Tamura T, Shinkai T, et al. Phase I and pharmacological study of paclitaxel given over 3 h with cisplatin for advanced non-small cell lung cancer. *Jpn J Clin Oncol*. 2001;31(3):93–9.
29. Urien S, Lokiec F. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. *Br J Clin Pharmacol*. 2004;57(6):756–63.
30. Fuertes MA, Castilla J, Alonso C, Perez JM. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. *Curr Med Chem*. 2003;10(3):257–66.
31. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. *Nat Med*. 2003;9(5):568–74.
32. Jacquemont C, Simon JA, D'Andrea AD, Taniguchi T. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. *Mol Cancer*. 2012;11:26.
33. Neuzil J, Stantic M, Zabalova R, et al. Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name? *Biochem Biophys Res Commun*. 2007;355(4):855–9.
34. Malik B, Nie D. Cancer stem cells and resistance to chemo and radio therapy. *Front Biosci (Elite Ed)*. 2012;4:2142–9.
35. Yu Y, Ramena G, Elble RC. The role of cancer stem cells in relapse of solid tumors. *Front Biosci (Elite Ed)*. 2012;4:1528–41.
36. Robertson FM, Ogasawara MA, Ye Z, et al. Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotype. *J Biomol Screen*. 2010;15(7):820–9.
37. Abelson S, Shamai Y, Berger L, Shouval R, Skorecki K, Tzukerman M. Intratumoral heterogeneity in the self-renewal and tumorigenic differentiation of ovarian cancer. *Stem Cells*. 2012;30(3):415–24.
38. Silva IA, Bai S, McLean K, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. *Cancer Res*. 2011;71(11):3991–4001.
39. Kryczek I, Liu S, Roh M, et al. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. *Int J Cancer*. 2012;130(1):29–39.
40. Baba T, Convery PA, Matsumura N, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. *Oncogene*. 2009;28(2):209–18.
41. Ferrandina G, Bonanno G, Pierelli L, et al. Expression of CD133-1 and CD133-2 in ovarian cancer. *Int J Gynecol Cancer*. 2007;18(3):506–14.
42. Curley MD, Therrien VA, Cummings CL, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. *Stem Cells*. 2009;27(12):2875–83.
43. Long H, Xie R, Xiang T, et al. Autocrine CCL5 signaling promotes invasion and migration of CD133(+) ovarian cancer stem-like cells via NF-kappaB-mediated MMP-9 upregulation. *Stem Cells*. 2012;30(10):2309–19.
44. Curley MD, Garrett LA, Schorge JO, Foster R, Rueda BR. Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. *Front Biosci*. 2011;16:368–92.
45. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. *Cell Cycle*. 2009;8(20):3274–84.
46. Cairney CJ, Bilsland AE, Evans TR, et al. Cancer cell senescence: a new frontier in drug development. *Drug Discov Today*. 2012;17(5–6):269–76.
47. Acosta JC, Gil J. Senescence: a new weapon for cancer therapy. *Trends Cell Biol*. 2012;22(4):211–9.
48. Schmitt CA. Cellular senescence and cancer treatment. *Biochim Biophys Acta*. 2007;1775(1):5–20.
49. Beausejour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. *EMBO J*. 2003;22(16):4212–22.
50. Roberson RS, Kussick SJ, Vallieres E, Chen SY, Wu DY. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. *Cancer Res*. 2005;65(7):2795–803.
51. Sliwinski MA, Mosieniak G, Wolanin K, et al. Induction of senescence with doxorubicin leads to increased genomic instability of HCT116 cells. *Mech Ageing Dev*. 2009;130(1–2):24–32.
52. La Porta CA, Zapperi S, Sethna JP. Senescent cells in growing tumors: population dynamics and cancer stem cells. *PLoS Comput Biol*. 2012;8(1):e1002316.
53. Achuthan S, Santhoshkumar TR, Prabhakar J, Nair SA, Pillai MR. Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species. *J Biol Chem*. 2011;286(43):37813–29.
54. Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. *Cell*. 2010;141(1):69–80.
55. Mosieniak G, Sikora E. Polyploidy: the link between senescence and cancer. *Curr Pharm Des*. 2010;16(6):734–40.
56. Erenpreisa J, Kalejs M, Cragg MS. Mitotic catastrophe and endomitosis in tumour cells: an evolutionary key to a molecular solution. *Cell Biol Int*. 2005;29(12):1012–8.
57. Vakifahmetoglu H, Olsson M, Zhivotovsky B. Death through a tragedy: mitotic catastrophe. *Cell Death Differ*. 2008;15(7):1153–62.
58. Vakifahmetoglu H, Olsson M, Tamm C, Heidari N, Orrenius S, Zhivotovsky B. DNA damage induces two distinct modes of cell death in ovarian carcinomas. *Cell Death Differ*. 2008;15(3):555–66.
59. Vitale I, Galluzzi L, Senovilla L, et al. Illicit survival of cancer cells during polyploidization and depolyploidization. *Cell Death Differ*. 2011;18(9):1403–13.



60. Puig PE, Guilly MN, Bouchot A, et al. Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. *Cell Biol Int*. 2008;32(9):1031–43.
61. Sundaram M, Guernsey DL, Rajaraman MM, Rajaraman R. Neosis: a novel type of cell division in cancer. *Cancer Biol Ther*. 2004;3(2):207–18.
62. Rajaraman R, Rajaraman MM, Rajaraman SR, Guernsey DL. Neosis—a paradigm of self-renewal in cancer. *Cell Biol Int*. 2005;29(12):1084–97.
63. Ianzini F, Kosmacek EA, Nelson ES, et al. Activation of meiosis-specific genes is associated with depolyploidization of human tumor cells following radiation-induced mitotic catastrophe. *Cancer Res*. 2009;69(6):2296–304.
64. Salmina K, Jankevics E, Huna A, et al. Up-regulation of the embryonic self-renewal network through reversible polyploidy in irradiated p53-mutant tumour cells. *Exp Cell Res*. 2010;316(13):2099–112.
65. Erenpreisa J, Salmina K, Huna A, et al. Polyploid tumour cells elicit paraploid progeny through depolyploidizing divisions and regulated autophagic degradation. *Cell Biol Int*. 2011;35(7):687–95.
66. Amaravadi RK. Autophagy-induced tumor dormancy in ovarian cancer. *J Clin Invest*. 2008;118(12):3837–40.
67. Almog N. Molecular mechanisms underlying tumor dormancy. *Cancer Letters*. 2010;294(2):139–46.
68. Lu Z, Luo RZ, Lu Y, et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. *J Clin Invest*. 2008;118(12):3917–29.
69. White DE, Rayment JH, Muller WJ. Addressing the role of cell adhesion in tumor cell dormancy. *Cell Cycle*. 2006;5(16):1756–9.
70. Bast RC Jr, Spriggs DR. More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. *Gynecol Oncol*. 2011;121(3):429–30.
71. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. *Lancet*. 2010;376(9747):1155–63.
72. Goonewardene TI, Hall MR, Rustin GJ. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. *Lancet Oncol*. 2007;8(9):813–21.
73. Licun W, Tannock IF. Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy. *Clin Cancer Res*. 2003;9(12):4614–8.
74. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. *Cancer Res*. 2005;65(7):2825–31.